Relmada Therapeutics (RLMD) Other financing activities (2014 - 2026)

Relmada Therapeutics (RLMD) has 5 years of Other financing activities data on file, last reported at $65651.0 in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $65651.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $238138.0 (changed N/A YoY) and the FY2025 annual result came in at $73021.0, down 74.56% from the prior year.
• Other financing activities retreated to $65651.0 in Q1 2026 per RLMD's latest filing, from $172487.0 in the prior quarter.
• Across five years, Other financing activities topped out at $12.3 million in Q2 2022 and bottomed at -$77.5 million in Q4 2022.
• The 4-year median for Other financing activities is $4.3 million (2022), against an average of -$3.7 million.
• Peak annual rise in Other financing activities reached 100.51% in 2024, while the deepest fall reached 99.78% in 2024.
• Tracing RLMD's Other financing activities over 4 years: stood at -$77.5 million in 2022, then jumped by 56.37% to -$33.8 million in 2023, then surged by 100.51% to $172487.0 in 2024, then tumbled by 61.94% to $65651.0 in 2026.
• Per Business Quant, the three latest RLMD Other financing activities figures stand at $65651.0 (Q1 2026), $172487.0 (Q4 2024), and $89601.0 (Q3 2024).

Peer Comparison